ORIGINAL ARTICLES
Department of Medicinal Chemistry, Faculty of Life Sciences, University Vienna, Austria
Determination of (R,R)-glycopyrronium bromide and its related impurities
by ion-pair HPLC
Dedicated to Professor Wilhelm Fleischhacker with the best wishes on occasion of his 75th birthday
D. Nebiu, M. Walter, B. Lachmann, H. Kopelent, C. R. Noe
Received October 12, 2006, accepted November 10, 2006
Prof. Dr. Christian R. Noe, Department of Medicinal Chemistry, University Vienna, Center of Pharmacy,
Althanstr. 14, 1090 Vienna, Austria
christian.noe@univie.ac.at
Pharmazie 62: 406–410 (2007)
doi: 10.1691/ph.2007.6.6220
A simple, rapid and specific ion-pair HPLC method for the determination of (R,R)-glycopyrronium bromide and its related impurities is presented, and parameters affecting the chromatographic properties
of these compounds are discussed. Optimal analyte separation was achieved on base deactivated
Nucleosil at 40 C, using phosphate buffer pH 2.30 with sodium-1-decanesulfonate (0.01 M)/methanol
(35/65; v/v) as eluent for isocratic elution at a flow rate 1ml min1. The analytical assay was validated
according to international guidelines. The method is suitable for in-process control and as stability
indicating assay.
1. Introduction
3-[(Cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl-pyrrolidinium bromide (INN: glycopyrronium bromide; market as a racemic drug, often under the USAN-term glycopyrrolate) belongs to the synthetic anticholinergic agents,
a class of drugs which competitively antagonise the effects
of acetylcholine competing with this neurohormone for
cholinergic receptor sites (Rama Sastry 1996). Consequently, the drug has been investigated for the management of chronic obstructive pulmonary disease and bronchial asthma (Cydulka and Emerman 1995; Gilman et al.
1990; Hansel 2005; Villetti et al. 2006), hyperhydrosis
(Wohlrab 2003), urine storage failure (Levin and Wein
1982), treatment of allergic rhinitis (Weinstein and Weinstein 2000), management of peptic ulcer (Miettinen et al.
1985) and as postoperative medication (Biwas et al. 2002).
In order to increase muscarinic receptor subtype selectivity
and to abolish unwanted side effects, enantiomerically
pure (R,R)-glycopyrronium bromide has been designed
(Czeche et al. 1997; Noe et al. 1999). A new, improved
route of (R,R)-glycopyrronium bromide synthesis has been
developed in our group (Noe and Walter 2002), consequently appropriate methods to determine its potential impurities and to monitor the reaction process (Scheme) are
needed. These analytical steps are important, especially
since (R,R)-glycopyrronium bromide is currently clinically
developed for the treatment of chronic obstructive pulmonary disease (COPD) by MEDA Pharma (Guera et al.
2006).
The final intermediate 5 as tertiary amine easily might
pass the blood brain barrier and induce unwanted effects.
Therefore, special emphasis should be placed on monitoring this potential impurity. Impurity 3 can result as decomposition product of (R,R)-glycopyrronium after hydro406
lytic cleavage of the ester functionality, and represents a
biotransformation product of active compound as well.
Previously reported analytical techniques for determination
of glycopyrronium bromide were based on HPLC/MS
(Matassa et al. 1992), GC/MS (Murray et al. 1984), CE/MS
(Tang et al. 2001); high-flow ion spray HPLC/MS (Hopfgartner et al. 1993); normal and reverse phase TLC
(Ojanpera et al. 1991); and spectrophotometry (Ebeid et al.
1986). The USP 25 monograph “glycopyrrolate injection”
employs an RP-HPLC assay using sodium-1-pentanesulfonate as an ion-pairing agent (USP 25th Ed. 1995). Chromatography with b-cyclodextrine as chiral stationary
phase has been proposed for the determination of glycopyrronium bromide diastereomers (Demian and Gripshover 1990).
Investigations aimed at the determination of (R,R)-glycopyrronium bromide and its related impurities have not
H
O
HO
O
HO
O
O
N
5
4
H3C
N + Br
CH3
CH3
R
HO
H
O
HO
O R
1
O
O
H3C
N + Br
CH3
O
HO
2
N
CH3
OH
3
Pharmazie 62 (2007) 6
ORIGINAL ARTICLES
Scheme
12
Impurities 2,4
Impurity 3
Glycopyrronium
Impurity 5
OH
10
R
O
+
L-4-Hydroxyproline
N
O CH3
Retention time (min)
HO
CH3
N-methylpyrrolidin-3-ol
racemate
O
HO
8
6
4
O R
2
quaternization
N
5
0
CH3
45
50
O
HO
R
HO
O
O R
60
65
70
75
O R
N + Br
CH3
H3 C
Fig. 1: Retension times of 1, 2, 3, 4 and 5 at different methanol content. Mobile phase: methanol (50–70%) : ammonium acetate buffer, 20 mM,
pH 4.00; sodium pentanesulfonate (0.01 M)
resolution
(3R,2'R) and (3S,2'R)
8
1
55
Methanol content (vol%)
N + Br
CH3
H3 C
Impurities 2,4
Impurity 3
Glycopyrronium
Impurity 5
7
been published hitherto. The purpose of the present study
was to develop a simple, rapid, and sensitive method for
simultaneous determination of (R,R)-glycopyrronium bromide and its potential impurities which arise during the
synthesis process, and as a stability indicating assay with
respect to degradation product 3.
Retention time (min)
6
5
4
3
2
1
2. Investigations, results and discussion
0
3.5
4
4.5
5
5.5
6
6.5
2.1. Optimization of the chromatographic conditions
Considering the structure of the polar and basic analytes
severe peak tailing could be presumed when using unmodified RP phases, therefore a base deactivated end-capped
stationary phase was included in the investigation. Initial
studies were performed with two types of mobile phase
modifiers: acetonitrile and methanol. Acetonitrile, due to
its high elutive power, in all cases provided very fast elution and poor selectivity for all compounds studied. Therefore, all subsequent studies were performed employing
methanol. As aqueous component of the eluent ammonium acetate buffer, 20 mM, pH 4.00; 4.50; 5.00 and 6.00,
and phosphate buffer, pH 2.30, respectively, were tested
for their suitability. The influence of the addition of ion
pair reagents was studied as well as different column temperatures.
2.1.1. Eluent composition
Ammonium acetate buffer system pH 4.00; 4.50; 5.00; 6.00
Initial experiments indicated that the shape of peaks from
(R,R)-glycopyrronium bromide and impurity 5 result as
highly asymmetric, therefore, utilization of an ion pair additive was considered. Variations of the aqueous component of the eluent with respect to pH and to type of the
ion pairing reagent proved that chromatographic retention
Pharmazie 62 (2007) 6
Fig. 2: Influence of the pH value on the retention of 1, 2, 3, 4 and 5.
Mobile phase: methanol : ammonium acetate buffer, 20 mM, 60 : 40
(V/V); sodium-1-pentanesulfonate (0.01 M)
of (R,R)-glycopyrronium bromide was not affected by pH
change but mainly by the lipophilicity of the ion pair created with the anionic reagent and/or the ion-exchange process involved with the sodium ions from sorbed reagent
molecules at the stationary phase. Retention of compound
5 was strongly dependent from the ion-pair reagent type
as well as the pH value. Naturally the influence of the ion
pairing on the chromatographic behaviour of 5 was more
distinct at lower pH, at pH values between 4.0 and 6.0
both factors were equally significant (Fig. 1). As evident,
the retention of mandelic acid derivative 3 was affected by
the pH value only (Fig. 2). The ion pairing with sodium1-pentanesulfonate 0.01 M lead to separation of the critical peaks of 1 and 5, nevertheless the peak symmetry was
unsatisfactory. Though reasonable capacity factors for
compounds 1 and 5 were found with eluents consisting of
methanol: ammonium acetate; 60 : 40 (v/v), at pH 4.00
and 6.00, respectively, containing sodium-1-decanesulfonate, the assymetry factor did not satisfy. Mandelic acid
derivative 3 eluted very fast (k0 < 2) under these conditions.
407
ORIGINAL ARTICLES
Phosphate buffer pH 2.30
At all ratios of eluent components the cationic derivatives
eluted very early without the use of ion pair reagents,
peak tailing was observed especially with compounds 1
and 5. Impurity 3 naturally had a high retention time. In
order to allow isocratic elution, ion pair reagents were
used to selectively increase the retention of the cationic
compounds relative to impurity 3. Sodium-1-pentanesulfonate increased the retention of all ionic and ionizable compounds, compound 3 naturally was not affected (Fig. 3).
At higher methanol percentages critical peaks (1 and impurity 5) were not efficiently resolved, lower amounts of
methanol led to unsuitably long retention times. Aiming
for fast analysis with appropriate retention range, possibly
2 k0 5, ion-pairing reagents of higher molecular size
as sodium-1-dodecanesulfonate and sodium-1-decanesulfonate were considered, the latter proved to be better suitable (Fig. 4). At 65% methanol, this ion-pair reagent afforded baseline resolution for 1, 3 and 5, impurities 2 and
4 co-eluted.
Summarizing, it can be stated that lower pH of the eluent
and higher modifier percentages together with a more hydrophobic ion pairing agent attained good resolution com-
Table 1: Influence of stationary phase on peak asymmetry.
Mobile phase: methanol : ammonium acetate buffer
20 mM, pH 4.00, 70 : 30 (v/v); sodium-1-pentanesulfonate (0.01 M)
Column type
Asymmetry factor
Nucleosil 100-5C-18 HD
LiChrospher 100-RP 18
(R,R)-Glycopyrronium
Impurity 5
2.14
2.87
1.9
3.3
Table 2: Influence of stationary phase on peak asymmetry.
Mobile phase: methanol : phosphate buffer, pH 2.30,
65 : 35 (v/v); sodium-1-decanesulfonate (0.01 M)
Column type
Asymmetry factor
Nucleosil 100-5C-18 HD
LiChrospher 100-RP 18
(R,R)-Glycopyrronium
Impurity 5
1.22
1.99
1.31
1.91
bined with satisfactory peak shapes. Accordingly, methanol/
phosphate buffer pH 2.30 with sodium-1-decanesulfonate
0.01 M (65 : 35, v/v) was selected as the most suitable mobile phase solution which was used for further optimization studies.
18
Impurities 2 and 4
Impurity 3
Glycopyrronium
Impurity 5
16
Retention time (min)
14
2.1.2. Stationary phase
A common octadecyl silica, LiChrospher 100-RP 18 column was compared with a base deactivated Nucleosil 1005C-18 HD column. As expected, the reduction of the influence of the free silanol groups considerably improved
peak shapes. The selection of a lower eluent pH led to
additional improvement of the peak symmetry (Tables 1
and 2).
12
10
8
6
2.1.3. Column temperature
4
2
0
45
50
55
60
65
70
75
Methanol content (vol%)
Fig. 3: Retension times of 1, 2, 3, 4 and 5 at different methanol content.
Mobile phase: methanol (50–70%) : phosphate buffer, pH 2.30; sodium-1-pentanesulfonate (0.01 M)
Retention time (min)
2.2. Method validation
This method has been substantiated with the determination
of specificity, linearity, precision, accuracy, limits of detection and limits of quantitation, according ICH guidelines
(ICH Harmonised Tripartite Guidelines 1994, 1996). The
25
Impurities 2,4
Impurity 3
Glycopyrronium
Impurity 5
20
The influence of temperature was studied in the range 20
to 60 C. A temperature of 40 C resulted as optimal affording a short analysis time (less than 7 min) and adequate resolution between critical peaks of glycopyrronium
bromide 1 and impurity 5 (Rs > 2). All ensuing analyses
for the quantification of impurities thereafter were carried
out at 40 C (Table 3 and Fig.5).
15
Table 3: Influence of column temperature in chromatographic
retention. (Mobile phase : methanol : phosphate buffer, pH 2.30, 65 : 35 (v/v); sodium-1-decanesulfonate
(0.01 M)
10
Temp. C
5
Retention time, min
3
1
5
4.69
4.18
3.91
3.56
2.80
9.15
7.30
6.17
5.00
3.30
11.70
8.66
7.29
6.00
3.40
0
58
60
62
64
66
68
Methanol content (vol%)
70
72
Fig. 4: Retension times of 1, 2, 3, 4 and 5 at different methanol content.
Mobile phase: methanol (60–70%) : phosphate buffer, pH 2.30; sodium-1-decanesulfonate (0.01 M)
408
20
25
30
40
60
Pharmazie 62 (2007) 6
ORIGINAL ARTICLES
Table 6: Limits of detection and limits of quantitation
80
AU (mV)
70
Glycopyrronium
(R,R)-Glycopyrronium bromide
Impurity 3
Impurity 5
60
LOD, mg ml1
LOQ, mg ml1
3.5103
1.5103
2.7103
1.0102
4.5103
8.2103
50
Impurities 2,4
40
Impurity 3
36
Impurity 5
30
1
2
3
4
5
6
7
AU (mV)
0
time (min)
Fig. 5: HPLC of (R,R)-glycopyrronium bromide 100 mg ml1 , spiked with
5% impurities (mobile phase: methanol : phosphate buffer, pH 2.30,
65 : 35 (v/v); sodium-1-decanesulfonate 0.01 M); Column temperature, 40 C)
35
Glycopyrronium
Compound 3
34
Compound 5
33
0
selectivity of the assay with respect to (R,R)-glycopyrronium bromide was assessed with injecting blank solution
and (R,R)-glycopyrronium bromide, and for impurities in
spiking experiments. No other signals appeared at the retention times of (R,R)-glycopyrronium bromide and its impurities.
Linear relationship was observed between detector signals
as a function of concentration of glycopyrronium 1, compounds 3 and 5. Regression line equations with their corresponding errors and squared correlation coefficients are
presented in Table 4. For impurity testing, spiking experiments with the known impurities have been used for the
evaluation of accuracy, which is reported as percentage of
recovery by the assay of known added amounts of compound 3 and compound 5. At each study, triplicates of samples are evaluated. The mean of triplicates was expressed
as recovery %. For glycopyrronium and compounds 3 and
5 repeatability was evaluated by expressing the relative
standard deviation of triplicate injections of samples. Intermediate precision was evaluated for impurities 3 and 5. Accuracy (recovery values) at two different analysis days has
been used to indicate the intermediate precision of method
(Table 5). LOD and LOQ were assessed on the basis of the
standard deviation of the response and the slope of calibration curve (Table 6 and Fig. 6).
1
2
3
4
time (min)
5
6
7
Fig. 6: (R,R)-Glycopyrronium bromide (100 mg ml1 ) spiked with 0.1% impurities
3. Experimental
3.1. Materials and reagents
(R,R)-Glycopyrronium bromide; compounds 2, 3, 4 and 5 were synthesized
in our laboratory. Methanol and acetonitrile, HPLC grade, were purchased
from Acros Organics, Belgium. Sodium-1-pentanesulfonate and sodium-1decanesulfonate, analytical grade, Fluka Chemica GmbH, Switzerland; sodium-1-dodecanesulfonate, Merck, Germany. Phosphoric acid, Mallinkrodt
Baker B.V. Holland, ammonium acetate, Riedel-De Haen AG, Hannover
Germany, potassium dihydrogenphosphate, E. Merck, Darmstadt, Germany.
HPLC grade water was purchased from Fisher Chemicals, UK, ammonium
hydroxide and acetic acid from E. Merck Darmstadt, Germany.
3.2. Standard and sample preparation
A stock solution of (R,R)-glycopyrronium bromide (1 mg ml1) was prepared by dissolving 100 mg (R,R)-glycopyrronium bromide standard in
mobile phase (volumetric flask 100 ml). This solution was further diluted
with mobile phase to result in the appropriate concentrations to establish the
calibration function. The solution of highest concentration, 100 mg ml1,
was used as reference standard in spiking experiments with solutions of
impurities (compounds 2, 3, 4 and 5). Stock solutions of impurities
(0.2 mg ml1, compound 3 and 0.53 mg ml1, compound 5) were prepared dissolving accurately weighted substances in mobile phase and sub-
Table 4: Linearity parameters for compounds 1, 3, and 5
(R,R)-Glycopyrronium
Impurity 3
Impurity 5
Regression line Eq.
Sr
Sa
Sb
R2
A ¼ 6095.9XC 754.96
A ¼ 14208.13XC þ 1487.80
A ¼ 7863.7XC 225.93
1750.41
2334.47
634.56
21.10
362.43
35.54
967.7
1487.0
344.3
1.00
0.9981
0.9999
Table 5: Accuracy and repeatability of impurities 3 and 5
Impurity
level, %
Impurity 3
tR, min
5.0
2.5
0.5
0.25
0.1
0.05
Impurity 5
Concentration
tR, min
Concentration
min
RSD %
Observed
mg CI
RSD,
% n¼3
%R
%R
Second day
min
RSD %
Observed
mg CI
RSD, %
n¼3
%R
%R
Second day
3.61
3.60
3.59
3.60
3.71
3.55
0
0.14
0.14
0.22
1.74
0.73
4.92 0.13
2.52 0.12
0.4
0.02
0.28* 0.05
0.108* 0.03
0.056* 0.006
1.1
2.05
2.5
7.5
11.5
0.41
98.4
100.2
80.0
111.0
108.0
112.0
96.0
97.6
88.0
108.0
116.0
––
5.99
5.95
5.88
5.84
6.24
––
0.08
0.60
0.14
0.41
3.5
––
5.24 0.13
2.68 0.36
0.6 0.035
0.29 0.03
0.124 0.08
––
1.0
5.3
2.3
4.5
26
––
104.6
106.9
120.0
116.8
124.0
––
86.4
96.0
109.0
112.0
120.0
––
* Recovery values and respective areas were calculated directly on the basis of (R,R)-glycopyrronium bromide peaks
Pharmazie 62 (2007) 6
409
ORIGINAL ARTICLES
sequently diluting with the same solvent to 5; 2.5; 0.5; 0.25; 0.1 and
0.05%, relative to the amount of parent compound (R,R)-glycopyrronium
bromide, 100 mg ml1.
For construction of the calibration functions of impurities 3 and 5 their
stock solutions were diluted with mobile phase to obtain appropriate concentrations.
3.3. Instrumentation
The HPLC consisted of dual pump LC-10AD, Shimadzu; Rheodyne Injector Cotati, California USA, SPD-10A Shimadzu UV-VIS detector, and column thermostat SpH 99, Holland. Nucleosil 100-5 C-18 HD, octadecyl
base deactivated (5 mm, 1254 mm I.D) and LiChrospher 100-RP 18, octadecyl, (5 mm, 1254 mm I.D) columns were used.
3.4. Mobile phase and LC conditions
Phosphate buffer pH 2.30 was prepared dissolving 4.80 g phosphoric acid
85% and 6.66 g potassium dihydrogenphosphate in deionized water, adjusting to pH 2.30 with the phosphoric acid 85%, after that 1000 ml volume
was accurately obtained adding deionised water. Ammonium acetate buffer,
20 mM was prepared dissolving 1.542 g of ammonium acetate in deionised
water, adjusting the pH to the respective value with concentrated acetic
acid or ammonia, deionized water was added to give 1000 ml.
Accurately weighed ion-pairing reagents were dissolved in aqueous portions
of mobile phase which was further mixed with organic phase and this solution was finally filtered through a Millipore 0.5 mm filter and degassed in
Ultrasonic Bath Starsonic 60 for 10 min before each run.
The chromatographic runs were performed in isocratic mode, mobile phase
flow rate 1.0 ml min1, and volume of injection 20 ml.
Acknowledgements: Mr. Nebiu acknowledges financial support by a grant of
the OeAD/University of Vienna.
References
Biwas SC, Biwas BN, Rudra A, Pan A (2002) A comparative study of
metoclopramide, glycopyrrolate and combination of metoclopramide and
glycopyrrolate in control of intraoperative and postoperative nausea and
vomiting after spinal anesthesia for cesarean section. J Obstetrics Gyn
India 52: 73–75.
Cydulka RK, Emerman CL (1995) Effects of combined treatment with
glycopyrrolate and albuterol in acute exacerbation of chronic obstructive
pulmonary disease. Ann Emerg Med 25: 470–473.
Czeche S, Elgert M, Noe C, Waelbroeck M, Mutschler E, Lambrecht G
(1997) Antimuscarinic properties of the stereoisomers of glycopyrronium bromide. Life Sci 60: 1167.
Demian J, Gripshover DF (1990) High-performance liquid chromatographic separation of 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide diastereoisomers. J Liq Chromatogr 13:
779–787.
Ebeid MY, Moussa BA, Abdel Malak AA (1986) Analysis of some antispasmodic drugs: oxyphencyclamine and glycopyrronium bromide.
Pharm Weekbl Sci Ed 8: 252–258.
Gilman MJ, Meyer L, Carter J, Slovis C (1990) Comparison of aerosolized
glycopyrrolate and metaproterenol in acute asthma. Chest 98: 1095–1098.
410
Guerra A, Campillo NE, Paez JA (2006) Glycopyrrolate combinations for
the treatment of respiratory diseases. Expert Opin Ther Patents 16: 723–
728.
Hansel TT, Neighbour H, Erin EM, Tan AJ, Tennant RC, Maus JG, Barnes PJ
(2005) Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest 128 : 1974–1979.
Hopfgartner G, Wachts T, Bean K, Henion J (1993) High-flow ion spray
liquid chromatography/mass spectrometry. Anal Chem 65: 439–446.
ICH (1996) Harmonized Tripartite Guideline on Validation of Analytical
Procedures: Methodology, International Conference on Harmonization.
ICH (1994) Harmonized Tripartite Guideline Text on Validation of Analytical Procedures, International Conference on Harmonization.
Levin RM, Wein RJ (1982) Direct measurement of the anticholinergic activity of a series of pharmacological compounds on the canine and rabbit urinary bladder. J Urol 128: 396–398.
Matassa LC, Woodward D, Leavitt LK, Firby P, Beaumier P (1992) Solidphase extraction techniques for the determination of glycopyrrolate from
equine urine by liquid chromatography-tandem mass spectrometry. J
Chromatogr 573: 43–48.
Miettinen P, Anttonen V, Aukee S, Huttunen R, Lahtinen J, Poikolainen E,
Paakkonen M, Tammela T (1985) Ranitidine versus anticholinergic/antacid for duodenal ulcer. A randomized, endoscopically controlled, singleblind multicentre trial. Scand J Gastroenterol 20: 701–705.
Murray GR, Calvey TN, Williams NE, Chan K (1984) Quantitative capillary gas chromatographic determination of glycopyrronium in human
plasma. J Chromatogr 308: 143–151.
Noe C, Mutschler E, Lambrecht G, Elgert M, Czeche S, Waelbroeck M
(1999) Pure enantiomer basic-aryl-cycloalkyl-hydroxycarboxylic acid esters, process for preparing the same and their use in medicaments. PCT/
AT 97/00245/1999, 1–27.
Noe C, Walter M, Verfahren zur Herstellung der R,R oder S,S konfigurierten Glykopyrronium-Isomere. Pat-Appl.: A 1896/2002 and Walter M,
PhD Thesis in Progress.
Ojanpera I, Vartiovaara J, Ruohonen A, Vuori E (1991) Combined use of
normal and reversed-phase thin-layer chromatography in the screening
for basic and quaternary drugs. J Liq Chromatogr 14: 1435–1446.
Rama Sastry BV (1996) Anticholinergic drugs. In: Wolff ME (Ed), Burgers medicinal chemistry and drug discovery. Vol. 2, A Wiley Interscience Publication p. 59–117.
Tang FP, Leung GN, Wan TS (2001) Analyses of quaternary ammonium
drugs in horse urine by capillary electrophoresis-mass spectrometry.
Electrophoresis 22: 2201–2209.
The United States Pharmacopoeia, 25th ed, Rockville, MD, USA, 1995,
pp. 811–812.
Villetti G, Bergamaschi M, Bassani F, Bolzoni PT, Harrison S, Gigli PM,
Janni A, Geppetti P, Civelli M, Patacchini R (2006) Pharmacological
assessment of the duration of action of glycopyrrolate vs tiotropium and
ipratropium in guinea-pig and human airways. Br J Pharmacol 148:
291–298.
Weinstein RE, Weinstein AM (2000) Nonsedating formulations for allergic
rhinitis which possess antihistaminic and anticholinergic activity. US
Pat. No: US6086914, 3.
Wohlrab J (2003) Topical formulation containing glycopyrronium bromide
for the therapy and prophylaxis of hyperhidrosis. PCT Int Appl Nr:
WO200301340, 24.
Pharmazie 62 (2007) 6